Bizzell Awarded Three SAMHSA IDIQ Domains

Bizzell Awarded Three SAMHSA IDIQ Domains

The Bizzell Group  (Bizzell) is excited to continue its successful partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) on the SAMHSA Indefinite Delivery Indefinite Quantity (IDIQ) contract through 2022. The firm was awarded three domains as a prime contractor on the IDIQ contract, and teamed with larger firms who were successful on additional domains. The contract is designed to assist SAMHSA in achieving its goal of reducing the impact of substance abuse and mental illness in America’s communities.

As a prime contractor, Bizzell, along with our partners, will provide assistance in three separate domains (Domain III, Domain V and Domain VI):

Domain III—Policy Analysis and Program Related Projects: Bizzell will assist with policy analysis, regulatory policy, developing programs and program support by organizing focus groups and consultations that will shed light on mental illness and substance use disorders, healthcare and behavioral health disparities as well as other health related topics.

Domain V—Technical Assistance and Training Projects: With Domain V, Bizzell will provide technical assistance and training courses for a wide range of topics including needs assessment, program planning, science-based approaches to prevention and treatment, payment and financing strategies, including managed care, disparities and culturally appropriate/responsive practice, trauma, health information technology, performance measurement, evaluation, and clinical and medical programs, practices and research.

Domain VI—Planning, Implementation and Report Support Projects: The focus of Domain VI is to plan and support multiple concurrent events and activities through the entire planning and logistical support lifecycle.

Aside from the three domains that Bizzell was awarded as a prime, the firm will also provide services to SAMHSA on two additional domains as a subcontractor to larger firms.

Domain I—Feasibility, Pilot, and Evaluation Projects: On Domain I, Bizzell employees will assist the prime contractor and SAMHSA on executing feasibility studies that will determine if an organizational activity, treatment service, strategy, survey or statistical study will work as intended. Feasibility is followed by the Pilot, which will assess whether the results of a feasibility study can be successfully scaled under a broader range of circumstances. The final portion is Evaluation, which will measure relevant aspects of program performance.

Domain IV—Communication Projects: Bizzell employees will assist with conceptualizing, planning, researching, designing, implementing and evaluating the effectiveness of communications projects that will increase awareness and educate stakeholders about SAMHSA’s mission to reduce the impact of substance abuse and mental health on America’s communities.

Bizzell Partners With CDC to Assist in Unintentional Injury Prevention Initiatives

Bizzell Partners With CDC to Assist in Unintentional Injury Prevention Initiatives

The Bizzell Group (Bizzell) is pleased to kick off the new year with a new opportunity with the Centers of Disease Control and Prevention’s (CDC), National Center for Injury Prevention and Control (NCIPC), Division of Unintentional Injury Prevention (DUIP).

Unintentional injuries, such as falls, car accidents and drug overdoses, are the number three cause of deaths in the United States, and they account for one of every four people treated in an emergency department. Bizzell has an extensive portfolio of supporting injury prevention initiatives related to roadway safety and substance abuse prevention. Therefore, the firm brings a deep working knowledge and understanding to CDC’s injury prevention objectives.

Bizzell’s commitment will include scientific injury prevention consulting, assistance and support services within DUIP. This includes assisting with the preparation of reports, presentations and papers for publication in scientific journals. The firm will identify evidence-based strategies for states to use in preventing injuries, as well as work directly with CDC scientists to exchange ideas on DUIP products that are related to concussions, global traffic injury and falls prevention. Additionally, Bizzell will focus on preparing summary documents for the Office of Global Health on DUIP’s motor vehicle projects, and provide expertise on the development and evaluation of injury modules for the Field Epidemiology Training Program (FETP) in the Center for Global Health.

“Injuries and violence affect everyone, regardless of age, race or economic status. And in the first half of life, more Americans die from violence and injuries than any other cause,” stated Chad Brown, Vice President of Strategy and Business Development for Bizzell. “Bizzell is pleased to offer its expertise and support to CDC in order to collectively develop innovations and solutions as we look to promote improved health and mortality outcomes.”

Bizzell looks forward to its continued partnership with CDC.

Bizzell Develops Medscape Article on the Interactions Between Dementia, Diabetes and Cardiovascular Disease

Bizzell Develops Medscape Article on the Interactions Between Dementia, Diabetes and Cardiovascular Disease

The Bizzell Group (Bizzell) has recently developed an article, published on Medscape, which explores the interactions between dementia, diabetes, and cardiovascular disease.  The article, Bidirectional Impact of Alzheimer’s Disease and Common Comorbid Conditions, is available as an online CME activity and was developed under a contract with the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA) in collaboration with the HHS, Office of Women’s Health.

It is intended for primary care providers, neurologists, psychiatrists, geriatricians, and other health care team members and addresses the complexities of treating patients with Alzheimer’s disease and common coexisting conditions, specifically cardiovascular disease (CVD) and diabetes (T2D).

These comorbidities can impact the severity and progression of the disease and require individualized, patient-centered approaches and thoughtful medical reasoning. The module discusses common challenges and considerations in the identification, diagnosis, and treatment of patients with Alzheimer’s disease and T2D or CVD.  Useful diagnostic tools, guidelines, and patient resources are provided.

Bizzell CEO Appointed to CSAP National Advisory Council

Bizzell CEO Appointed to CSAP National Advisory Council

In recognition of his extensive expertise in substance abuse prevention and treatment, Anton Bizzell, M.D., CEO of The Bizzell Group (Bizzell), has been appointed by the Secretary of the U.S. Department of Health and Human Services (HHS) to serve on the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention (CSAP) National Advisory Council. Dr. Bizzell’s appointment is effective through November 2018.

CSAP leads the development of national substance abuse prevention policies and programming, promotes the adoption of proven, science-based substance abuse prevention approaches and helps states and communities build their capacity to implement these approaches. As a member of the CSAP National Advisory Council, Dr. Bizzell will support this mission by making recommendations on agency and center activities and policies, in addition to reviewing grant and cooperative agreement submissions. “It’s a great honor and responsibility to work at a national level to help states and communities find proven and practical ways to prevent substance abuse and reduce the impact this disease has on individuals, families and communities,” said Dr. Bizzell.

Since earning his Doctorate in Medicine from the University of Virginia, Dr. Bizzell has spent the majority of his career working to improve access and quality of care issues for people experiencing substance abuse, mental illness or complicating health issues. He has more than 20 years of combined clinical, research, health services, policy and management experiences with various private and public organizations, including his service as a Medical Officer at both the National Institute on Alcohol Abuse and Alcoholism, NIH, and the Center for Substance Abuse Treatment, SAMHSA. Dr. Bizzell has also provided leadership to projects of national significance including CSAP’s Prevention Fellowship Program, SAMHSA’s Federal Drug Free Workplace Technical Support contract, and SAMHSA’s Prescription Drug Misuse and Abuse project.